Delivery Order SPE2DR25D2208-SPE2DR26FB4QL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,853.05 on August 7, 2025, for the supply of Novolog 100 Unit/mL Flexpen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. As a child order under a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,526.16 to AmerisourceBergen Drug Corp for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of September 22, 2025. The award was issued on September 19, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $5,279.79 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens, with completion expected by September 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,792.62 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,168.72 to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens. This firm fixed-price delivery order, which carries an ultimate completion date of December 2, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,830.66 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award was made on November 24, 2025, under a firm fixed-price contract type with an ultimate completion date of November 25, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency awarded a $1,827.81 delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens. This is a firm fixed price delivery order with an ultimate completion date of December 2, 2025, and represents a non-competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,976.49 by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. The contract operates under firm fixed-price terms with an ultimate completion date of September 29, 2025, and represents a non-set-aside, competitively awarded procurement. This delivery order is executed as a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,204.12 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. Issued on August 27, 2025, this firm fixed price delivery order is scheduled for completion by August 28, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under a larger contract vehicle and reflects the...
- The Defense Logistics Agency awarded a delivery order valued at $7,027.17 to AmerisourceBergen Drug Corp for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. The contract, issued on April 30, 2025, with an ultimate completion date of May 1, 2025, represents a firm fixed price delivery order with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- SPE2DR25D2208Indefinite Delivery Contract
- SPE2DR25D2208-SPE2DR26FB4QLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,464.90 to AmerisourceBergen Drug Corp for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens. This competitively awarded, firm fixed-price delivery order was issued on November 26, 2025, with an ultimate completion date of November 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order falls within AmerisourceBergen's existing pharmaceutical supply framework with the federal government. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. The award of this insulin product reflects the company's ongoing role in providing essential diabetes management medications and other specialized pharmaceutical commodities to support military medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 11/25/25 |